BioCryst Pharma (BCRX) Misses Q1 EPS by 8c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $10.99 --0%
EPS Growth %: +6.7%
Financial Fact:
Net loss: -11.53M
Today's EPS Names:
HELE, PSMT, LEVI, More
EPS Growth %: +6.7%
Financial Fact:
Net loss: -11.53M
Today's EPS Names:
HELE, PSMT, LEVI, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($0.31), $0.08 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $4.82 million versus the consensus estimate of $5.42 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook
- BioCryst Pharma (BCRX) PT Raised to $14 at RBC Capital
- JPMorgan Starts J&T Global Express (1519:HK) at Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
